The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review.

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY

European Journal of Contraception and Reproductive Health Care Pub Date : 2023-06-01 DOI:10.1080/13625187.2023.2197539

Giovanni Grandi, Gloria Guariglia, Fabio Facchinetti

{"title":"The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review.","authors":"Giovanni Grandi, Gloria Guariglia, Fabio Facchinetti","doi":"10.1080/13625187.2023.2197539","DOIUrl":null,"url":null,"abstract":"Introduction: Both Food and Drugs Administration and European Medicine Agency (EMA) approve the use of a triphasic combined oral contraceptive (COC) containing ethinyl-oestradiol (EE) and norgestimate (NGM) for acne vulgaris treatment in women requiring an effective contraception. COCs can target sebum production and may also play a role in decreasing follicular hyperkeratinisation.Results: Specific advantages of the use of an anti-androgenic progestin such as NGM in this condition are presented in this review, including the lowest venous thrombosis risk in the COCs scenario, as established by the EMA, associated with a very satisfactory cycle control. The results of aggregate analysis of published data (n = 163 vs. n = 161 treated subjects) demonstrate a significant effect in comparison with the placebo of a greater than 50% reduction, in terms of inflammatory lesions (from 19.0 to 8.2), comedones (from 35.2 to 17.7) and total lesions (from 54.3 to 25.9) count.Conclusions: The choice of a triphasic combination of EE/NGM seems a referenced, highly effective, easy-to-use and safe therapeutic approach for acne vulgaris, alone or in combination with different targeted drugs.","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Contraception and Reproductive Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13625187.2023.2197539","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Both Food and Drugs Administration and European Medicine Agency (EMA) approve the use of a triphasic combined oral contraceptive (COC) containing ethinyl-oestradiol (EE) and norgestimate (NGM) for acne vulgaris treatment in women requiring an effective contraception. COCs can target sebum production and may also play a role in decreasing follicular hyperkeratinisation.

Results: Specific advantages of the use of an anti-androgenic progestin such as NGM in this condition are presented in this review, including the lowest venous thrombosis risk in the COCs scenario, as established by the EMA, associated with a very satisfactory cycle control. The results of aggregate analysis of published data (n = 163 vs. n = 161 treated subjects) demonstrate a significant effect in comparison with the placebo of a greater than 50% reduction, in terms of inflammatory lesions (from 19.0 to 8.2), comedones (from 35.2 to 17.7) and total lesions (from 54.3 to 25.9) count.

Conclusions: The choice of a triphasic combination of EE/NGM seems a referenced, highly effective, easy-to-use and safe therapeutic approach for acne vulgaris, alone or in combination with different targeted drugs.

查看原文本刊更多论文

复方口服避孕药治疗寻常性痤疮的研究进展。

美国食品和药物管理局(fda)和欧洲药品管理局(EMA)批准使用含有乙炔雌二醇(EE)和诺格估计(NGM)的三相联合口服避孕药(COC)治疗需要有效避孕的妇女的寻常性痤疮。COCs可以靶向皮脂生成，也可能在减少毛囊角化过度中发挥作用。结果:本综述提出了在这种情况下使用抗雄激素黄体酮(如NGM)的具体优势，包括EMA确定的COCs情况下静脉血栓形成风险最低，与非常满意的周期控制相关。对已发表数据的汇总分析结果(n = 163 vs. n = 161治疗对象)表明，在炎症病变(从19.0减少到8.2)、粉刺(从35.2减少到17.7)和总病变(从54.3减少到25.9)计数方面，与安慰剂相比，显着效果减少了50%以上。结论:选择EE/NGM三期联合治疗寻常性痤疮，可单独或联合不同靶向药物治疗，是一种可参考、高效、易用、安全的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Contraception and Reproductive Health Care 医学-妇产科学

CiteScore

3.70

自引率

11.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.